Southeastem Clinical Research is categorized under Medical Research in Maitland, FL and active since 1988.
Southeastem Clinical Research was established in 1988, and today employs 1 to 4, earning Unknown per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 5419100 by the NAICS.
If you are seeking more information, feel free to contact John Byrnes, President at the company’s single location by writing to 531 Versailles Drive, Maitland, Florida FL 32751 or by phoning (407) 539-2000. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Southeastem Clinical Research |
| Contact Person: | John Byrnes, President |
| Address: | 531 Versailles Drive, Maitland, Florida 32751 |
| Phone Number: | (407) 539-2000 |
| Website Address: | seclinical.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 1988 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 5419100 |
| Share This Business: |
Southeastem Clinical Research was started in 1988 to provide professional Medical Research under the SIC code 8733 and NAICS code 5419100. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact John Byrnes, President for inquiries that concern Southeastem Clinical Research by calling the company number (407) 539-2000, as your correspondence is most welcome. Additionally, the physical location of the single location of Southeastem Clinical Research can be found at the coordinates 28.63536,-81.35994 as well as the street address 531 Versailles Drive in Maitland, Florida 32751.
For its online presence, you may visit Southeastem Clinical Research’s website at seclinical.com and engage with its social media outlets through on Twitter and on Facebook.